肿瘤细胞治疗研究
英文原题：Guest Editorial: what can be done to improve cancer immunotherapies?
Guest Editorial: what can be done to improve cancer immunotherapies?
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
过去十年中，包括免疫检查点抑制剂和CAR-T 细胞疗法等细胞治疗方案在内的癌症免疫治疗取得了显著进展。然而，由于抗肿瘤免疫调节的多种机制，包括肿瘤细胞和肿瘤微环境表达的免疫检查点分子、免疫抑制细胞以及肿瘤细胞衍生因子如细胞外囊泡等，这些癌症免疫疗法在某些患者群体中的疗效仍然有限。在本期PIH综述系列中，我们聚焦于改善癌症患者免疫治疗的新知识和策略。
Cancer immunotherapies including immune checkpoint inhibitor and cell-based regimens such as chimeric antigen receptor T cell therapy have progressed markedly in the last decade.
However, the efficacy of those cancer immunotherapies is still limited in some patient populations due to the many mechanisms of antitumor immunomodulation, including immune checkpoint molecules expressed by both tumor cells and the tumor microenvironment, immunosuppressive cells, and tumor cell-derived factors such as extracellular vesicles. In this PIH review series, we focus on new knowledge and strategies to improve immunotherapies for cancer patients.
MEMBER ACCOUNT
登录成功会直接打开下一页。
